関連する実験動画

Updated: May 11, 2026

Generation of Alginate Microspheres for Biomedical Applications
10:33

Generation of Alginate Microspheres for Biomedical Applications

Published on: August 12, 2012

21.0K

薬媒介システムとしてのイソマルト基マイクロファイバーの製造と評価

Andrea Kovács1, Bálint Attila Kecskés1, Gábor Filipszki1

  • 1Department of Pharmaceutics, Semmelweis University, Hőgyes E. Str. 7-9, 1092 Budapest, Hungary.

Pharmaceutics
|August 28, 2025
PubMed
まとめ

研究者はイソマルト基の微細繊維製薬システムを開発しました このシステムは,特定のイソマルト組成物とエタノール蒸気処理を用いて,安定性を高め,薬剤の迅速な放出を可能にし,先進的な医薬品の配合に道を開きます.

キーワード:
FlashDose®技術についてコットン・キャンディ・メソッドドラッグ・キャリア薬物投与システムフロス技術イソマルトメルト・スピニングマイクロファイバー経口分解錠剤 (ODT)

さらに関連する動画

Fabrication of Extracellular Matrix-derived Foams and Microcarriers as Tissue-specific Cell Culture and Delivery Platforms11:19

Fabrication of Extracellular Matrix-derived Foams and Microcarriers as Tissue-specific Cell Culture and Delivery Platforms

Published on: April 11, 2017

13.5K
3D Printing of In Vitro Hydrogel Microcarriers by Alternating Viscous-Inertial Force Jetting05:32

3D Printing of In Vitro Hydrogel Microcarriers by Alternating Viscous-Inertial Force Jetting

Published on: April 21, 2021

3.2K

関連する概念動画

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...